Last reviewed · How we verify
Intraoperative Intraosseous Vancomycin
Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, delivered intraoperatively into bone to prevent surgical site infections.
Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, delivered intraoperatively into bone to prevent surgical site infections. Used for Surgical site infection prophylaxis in orthopedic procedures.
At a glance
| Generic name | Intraoperative Intraosseous Vancomycin |
|---|---|
| Also known as | Vancomycin |
| Sponsor | OrthoCarolina Research Institute, Inc. |
| Drug class | Glycopeptide antibiotic |
| Target | Bacterial peptidoglycan (D-Ala-D-Ala) |
| Modality | Small molecule |
| Therapeutic area | Orthopedic Surgery / Surgical Prophylaxis |
| Phase | FDA-approved |
Mechanism of action
Vancomycin works by preventing cross-linking of peptidoglycan strands in bacterial cell walls, leading to cell wall instability and bacterial death. When administered intraoperatively as an intraosseous injection directly into bone, it achieves high local concentrations at the surgical site to prevent infection during orthopedic procedures. This local delivery approach minimizes systemic exposure while maximizing antimicrobial efficacy at the site of greatest infection risk.
Approved indications
- Surgical site infection prophylaxis in orthopedic procedures
Common side effects
- Local tissue irritation or inflammation at injection site
- Systemic hypersensitivity reactions (rare with local administration)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: